 

‘Suryoday Small Finance Bank Limited
Annexure 22 - Notes forming part of the Restated Summary Statements
(All amounts are in Indian Rupees in million unless otherwise stated)

1. Capital

1.1 Capi

 

I to Risk Weighted Assets Ratio (CRAR)

‘The following table sets forth, for the year indicated, computation of capital adequacy as per operating guidelines.

 

 

 

 

 

Particulars ‘As at December 31, | Asat December 31,2019 | AsatMarch 31,2020] AsatMarch3l, | AsatMarch 31,
2020 2019 2018
[Common equity ter I Capital ratio (0) 36.94%] 39.61%5| 34.30%| 0.2596
Tier 1 capital ratio (6) 36.94%| 39.61%| 34.30%| 0.25%
Tier 2 capital ratio (%) 4.2304 1.0294 1.14% 3.15%]
Total capital ratio ( CRAR) (6) A117 40.63% 35.4%5| 3.0%

 

 

Percentage of the shareholding of the Goverment oF
india in public sector banks

 

[Amount of Additional Tier I capital raised of which;

 

 

Perpetual Non Cumulative Preference Shares (PNCPS):

 

 

 

 

Perpetual Debt Instruments (PDD)

 

 

 

 

 

Subordinated debt (Tier 2 capital) outstanding as at December 31, 2020 is @ 1400 million, as at December 31, 2019 : 2 600 million, as at March 31, 2020 is ® 600 million, as at March

31, 2019 is 600 million as at March 31, 2018 is & 600 million,

‘The Bank has applied 100% risk weight on Advances charged as security against grandfathered borrowing on the date of conversion in to a small finance bank. The Bank has applied
to the RBI for approval of capital risk charge on advances secured against grandfathered borrowings.

Further as per RBI's directions given in the circular DBR.NBD.No. 4502/16.13.218/2017- 18, dated November 8, 2017, no separate risk charge has been calculated for Market Risk

and Operational Risk for capital ratios.

If the Bank considers Market Risk and Operational Risk then Total capital ratio would be 30.08% for December 31, 2020, 33.13% for December 31, 2019, 29.57% March 31, 2020,

35.03% for March 31, 2019 and 37.53% for March 31, 2018,

1.2 Capital Infusion

Capital infusion pursuant to ESOPs:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

Particulars During the period ended | During the period ended| During the year | During the year | During the year

December 31, 2020 December 31,2019 | ended March 31, | ended March 31, | ended March 31,

2020 2019 2018

[Number of Equity shares alloted with face value € 10 in respect of tock options 200,788 229,392 5,11,645| 283,727 331,982
exercised
[Aggregate consideration (including share premium) 28.97 28.50] 66.72] 32.76] 23.44]
Capital infusion pursuant to Private placement of Equity shares:
Particulars During the period ended | During the period ended| During the year | During the year | During the year

December 31, 2020 December 31,2019 | ended March 31, | ended March 31, | ended March 31,

2020 2019 2018
Pursuant to Shareholders’ approval, Number of Equity shares alloted with face 23,90,020) 45,00,000 45,00,000] 1,38,02,083 31,00,000
value € 10
[Aggregate consideration (including share premium) zal 630.00} 630.00] 2,484.37| 232.50]
Details of movement in the paid up equity share capital are as below:
Particular December 31, 2020 December 31, 2019 March 31, 2020 March 31, 2019 March 31, 2018
Equity shares ‘Amount Equity shares Amount] Equity shares ‘Amount| Equity shares| ‘Amount| Equity shares ‘Amount

[Equity shares atthe beginning of the period! year, 865,941 865.94 815,082,482 815.82 8,15,82,482 815.82 6,74,96,672 674.97 | __ 640,064,600 640.65)
[Addition pursuant to stock options exercised 2,00,788) 201 2,29,392 2.30 511,649 52 2,83,7 2.83 3,31,982 3.32]
[Addition pursuant to employee equity shares issued 23,90,020 23.90 45,00,000 5.00 15,00,000 45.00 7,38,02,083 138.02 31,00,000 31.00}
during the year
[Equity shares outstanding at the end of the period! 8,91,84,939 891.85 8,63,11,874 SRP 865,94,131 865.94 815,82,482 815.82 | _6,74,96,672 674.97
year

 

 
